Is high-dose chemotherapy dead?

European Journal of Cancer

Volumn 41, Issue 1, 2005, Pages 9-11

  Rodenhuis, Sjoerd ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; MELPHALAN; MITOXANTRONE; TAXANE DERIVATIVE; TRASTUZUMAB;

BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DNA MICROARRAY; DRUG COST; DRUG DOSE REDUCTION; DRUG MEGADOSE; GENE EXPRESSION; HUMAN; ONCOGENE NEU; PRIORITY JOURNAL; SHORT SURVEY;

EID: 11144318239     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2004.09.014     Document Type: Editorial

References (17)

1. W.P. Peters High-dose chemotherapy with autologous bone marrow transplantation for the treatment of breast cancer: yes V.T. DeVita S. Hellmann S.A. Rosenberg Important advances in oncology 1995 Lippincott Company Philadelphia 215 230
2. W.P. Peters, M. Ross, and J.J. Vredenburg High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk breast cancer J Clin Oncol 11 1993 1132 1143
3. E. Frei III, K. Antman, B. Teicher, P. Eder, and L. Schnipper Bone marrow autotransplantation for solid tumors prospects J Clin Oncol 7 1989 515 526
4. R.B. Weiss, R.M. Rifkin, F.M. Stewart, R.L. Theriault, L.A. Williams, and A.A. Herman High-dose chemotherapy for high-risk breast cancer: an on-site review of the Bezwoda study Lancet 355 2000 999 1003
5. Lotz JP, Curé H, Janvier M, Asselain B, Morvan F, Legros M, et al. High-dose chemotherapy with hematopoietic stem cells transplantation for metastatic breast cancer: final results of the French multicentric randomized CMA/PEGASE 04 protocol. Eur J Cancer 2004, this issue (doi: 10.1016/j.ejca.2004. 09.006).
6. E.A. Stadtmauer, A. O'Neill, L.J. Goldstein, P.A. Crilley, K.F. Mangan, and J.H. Ingle Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer N Engl J Med 342 2000 1069 1076
7. J.P. Crown, S. Leyvraz, M. Verrill, V. Guillem, A. Efremidis, and J. Gardia-Conde Bru Effect of tandem high-dose chemotherapy on long-term complete remissions in metastatic breast cancer, compared to conventional dose in patients who were not selection on basis of response to prior chemotherapy: mature results of the IBDIS-I Proc Am Soc Clin Oncol 23 2004 34 [Abstract 631]
8. Biron P, Durand M, Roche H, et al. High-dose thiotepa, cyclophosphamide and stem cell transplantation after 4 FEC 100 compared with 4 FEC alone allowed a better disease free survival but the same overall survival in first line chemotherapy for metastatic breast cancer. Results of the PEGASE 03 French Protocol. Proc Am Soc Clin Oncol 2002, 21, [Abstract 167]
9. M. Crump, S. Gluck, and D. Stewart A randomized trial of high-dose chemotherapy with autologous peripheral blood stem cell support compared to standard therapy in women with metastatic breast cancer: a National Cancer Institute of Cancer Clinical Trials Groups Study Proc Am Soc Clin Oncol 20 2001 [Abstract 82]
10. P. Schmid, H. Samonigg, and T. Nitsch Randomized trial of up-front tandem high-dose chemotherapy compared to standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer Proc Am Soc Clin Oncol 21 2002 [Abstract 171]
11. P.A. Greenberg, G.N. Hortobagyi, T.L. Smith, L.D. Ziegler, D.K. Frye, and A.U. Buzdar Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer J Clin Oncol 14 1996 2197 2205
12. F.R. Dunphy, G. Spitzer, and J.E. Rossiter Fornoff Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support Cancer 73 1994 2157 2167
13. L.J. Ayash, C. Wheeler, and D. Fairclough Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem cell support for advanced breast cancer J Clin Oncol 13 1995 2043 2049
14. Y. Nieto, S. Nawaz, and R.B. Jones Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer J Clin Oncol 20 2002 707 718
15. S. Rodenhuis, M. Bontenbal, L.V. Beex, J. Wagstaff, D.J. Richel, and M.A. Nooij Netherlands working party on autologous transplantation in solid tumors. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer N Engl J Med 349 2003 7 16
16. J. Bergh, T. Wiklund, B. Erikstein, E. Lidbrink, H. Lindman, and P. Malmstrom Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study Lancet 356 2000 1384 1391
17. J.C. Chang, E.C. Wooten, A. Tsimelzon, S.G. Hilsenbeck, M.C. Gutierrez, and R. Elledge Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer Lancet 362 2003 262 369